Irbesartan Hydrochlorothiazide Zentiva

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan Hydrochlorothiazide Zentiva, is an angiotensin II receptor blocker and thiazide diuretic presented as a tablet for oral use. It is used to lower blood pressure in adults with hypertension.

GNH USA supplies Irbesartan Hydrochlorothiazide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan Hydrochlorothiazide is an antihypertensive agent that acts on the renin‑angiotensin‑aldosterone system and renal sodium handling. - Hypertension: lowers systolic and diastolic blood pressure in patients with high blood pressure.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Mild electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia when combined with potassium‑sparing agents - Severe allergic reactions (e.g., angioedema, rash) - Pancreatitis - Blood dyscrasias (e.g., agranulocytosis)

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly: ensure adequate control and avoid excessive drops. - Assess renal function: check serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Check electrolytes: monitor potassium and sodium levels, adjusting concomitant diuretics as needed. - Avoid use in severe hepatic impairment: liver disease may alter drug metabolism. - Pregnancy category D: drug may cause fetal harm; contraindicated in the second and third trimesters. - Use caution in elderly patients: increased sensitivity to blood‑pressure changes. - Store at ambient temperature: keep in the original pack, protect from moisture.

Irbesartan Hydrochlorothiazide may interact with several medicines. Major Interactions (Avoid): - ACE inhibitors or other ARBs: risk of additive renal impairment and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - Lithium: increased lithium levels and toxicity. - NSAIDs: may reduce antihypertensive effect and impair renal function. - Other antihypertensives (e.g., beta‑blockers) in high doses: risk of excessive hypotension.

Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma levels. - Other thiazide diuretics: additive electrolyte disturbances. - Antidiabetic agents: diuretics may affect glucose control. - Beta‑blockers: monitor for bradycardia and hypotension. - Alcohol: may enhance dizziness and hypotensive effects.